Neurulation

Neurulation is a critical early embryological process that forms the entire central nervous system. It's a high-yield topic for finals because failures in this process lead to Neural Tube Defects (NTDs), which are common, preventable, and have significant clinical consequences. Understanding neurulation links directly to antenatal screening, public health advice (folic acid), and the multidisciplinary management of conditions like spina bifida. You need to know the timeline, key structures involved, and the derivatives of the neural tube and neural crest cells.

The neural tube, once closed, differentiates into the brain and spinal cord. Its inner lining, the neuroepithelium, gives rise to neuroblasts (neurons) and glioblasts (astrocytes, oligodendrocytes). The tube organises into distinct zones: the ventricular zone (proliferative), mantle zone (forms grey matter), and marginal zone (forms white matter). Crucially, in the spinal cord, the mantle zone divides into the alar plate (dorsal, sensory neurons) and the basal plate (ventral, motor neurons), separated by the sulcus limitans. This fundamental organisation dictates the sensory and motor functions of the spinal cord.

Neurulation is arguably one of the most clinically relevant embryological topics. Failure of neural tube closure results in Neural Tube Defects (NTDs). Anencephaly (failure of cranial neuropore closure) is lethal. Spina bifida (failure of caudal neuropore closure) has a spectrum of severity, from spina bifida occulta (often asymptomatic) to myelomeningocele (severe, involving spinal cord herniation). Disorders of neural crest cell migration (neurocristopathies) include Hirschsprung disease (aganglionic megacolon) and DiGeorge syndrome (thymic/parathyroid aplasia, cardiac defects). Recognising these conditions and understanding their embryological basis is key for diagnosis, counselling, and management. Folic acid supplementation is the cornerstone of prevention.

Antenatal screening is vital. Maternal serum alpha-fetoprotein (MSAFP) is measured at 16–18 weeks; elevated levels can indicate an open NTD. The definitive diagnostic tool is the mid-trimester 'anomaly scan' (ultrasound) performed around 20 weeks, which can directly visualise spinal defects (e.g., 'lemon sign' or 'banana sign' for spina bifida) and cranial defects (e.g., absence of cranial vault in anencephaly). Amniocentesis can also detect elevated alpha-fetoprotein and acetylcholinesterase in amniotic fluid.

Management of NTDs is multidisciplinary. For spina bifida, this often involves surgical closure (sometimes prenatally), neurosurgery for associated hydrocephalus (e.g., ventriculoperitoneal shunts), and long-term care addressing mobility issues, bladder and bowel dysfunction, and cognitive development. The primary preventative measure is periconceptional folic acid supplementation. Public health campaigns are crucial to ensure women are aware of the recommended doses and timing.